rs2040704 — RAD50 RAD50/IL13 5q31 Atopic March Locus

RAD50/IL13 5q31 — The Atopic March Locus: When Your Immune Defaults to Allergy

At position 5q31.1, squeezed between the DNA-repair gene RAD50¹¹ RAD50
RAD50 double-strand break repair protein; at this locus the gene's introns house regulatory elements controlling adjacent cytokine genes and the cytokine gene IL13²² IL13
Interleukin-13; a Th2 cytokine secreted by mast cells, basophils, and activated CD4+ T cells that drives IgE class switching, mucus hypersecretion, and smooth-muscle hyperresponsiveness, sits one of the most replicated immune-regulation loci in the human genome. GWAS studies have repeatedly flagged this region — designated 5q31 (RAD50-IL13 and IL4) — as a major determinant of total serum IgE levels and susceptibility to the full spectrum of atopic march³³ atopic march
the stereotyped progression from early-childhood eczema through food allergy, then asthma, then allergic rhinitis; driven by a shared Th2-skewed immune baseline that successive allergen exposures progressively unmask conditions. rs2040704 is an intronic variant in this regulatory hub — the G allele tags a chromatin state that amplifies Th2 cytokine output, raising IgE and lowering the threshold for allergic sensitization at every stage of the march.

The Mechanism

The intergenic space between RAD50 and IL13 is not empty. It contains the TH2 locus control region (TH2-LCR)⁴⁴ TH2 locus control region (TH2-LCR)
a cluster of DNase I hypersensitive sites (RHS4–RHS7) that act as long-range enhancers coordinating simultaneous IL-4, IL-5, and IL-13 transcription in activated Th2 cells; analogous to the beta-globin LCR — a collection of regulatory enhancer elements (RHS4–RHS7) that loop chromosomally to simultaneously activate IL-4, IL-5, and IL-13 when a T cell commits to the Th2 lineage. The rs2040704 G allele sits within this control region and tags a regulatory haplotype that alters DNA methylation at the IL13 promoter and modulates the expression of both IL13 and IL4 in an allele-specific manner — as demonstrated by Schieck et al. (2014), who showed allele-specific methylation differences at the TH2-LCR element RHS7⁵⁵ allele-specific methylation differences at the TH2-LCR element RHS7
Schieck M et al. Allergy 2014; rs2240032 in RHS7 shows allele-dependent methylation in cord blood and at 4.5 years, influencing downstream IL13 promoter methylation tracking from cord blood through early childhood.

When the enhancer hub is in the more active state tagged by the G allele, T cells that encounter allergens produce higher pulses of IL-13 and IL-4. IL-13 then acts directly on airway epithelium and smooth muscle — bypassing the IgE-mast-cell axis — to drive mucus hypersecretion, goblet-cell metaplasia, and smooth-muscle hyperresponsiveness⁶⁶ mucus hypersecretion, goblet-cell metaplasia, and smooth-muscle hyperresponsiveness
Wills-Karp & Chiaramonte Curr Opin Pulm Med 2003; mouse models showed IL-13 alone, without eosinophils or IgE, reproduces all hallmarks of allergic asthma. Simultaneously, IL-4 drives B-cell class switching to IgE. Higher ambient IgE sensitizes mast cells systemically, lowering the allergen threshold for urticaria, food reactions, and nasal symptoms — the allergic phenotype spreads across organ systems.

The Evidence

The 5q31 RAD50/IL13 locus is one of only a handful of immune-regulation loci with genome-wide significance for total serum IgE in multiple large cohorts. A comprehensive genome-wide association study of severe asthma by Li et al. (2010)⁷⁷ Li et al. (2010)
Li X et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol 2010 — 473 severe asthma cases and 1,892 controls — identified multiple significant SNPs in the RAD50-IL13 region, with the leading hit rs2244012 (intronic in RAD50) reaching P=3.04×10⁻⁷. The TH2 locus control region 3' of RAD50 was separately implicated by imputed variants, placing rs2040704's neighborhood at the mechanistic heart of this signal.

Fine-mapping by Sharma et al. (2014)⁸⁸ Sharma et al. (2014)
Sharma V et al. Fine-mapping of IgE-associated loci 1q23, 5q31, and 12q13 using 1000 Genomes Project data. Allergy 2014 in more than 1,300 German children confirmed 5q31 (RAD50-IL13 and IL4) as one of three major determinants of total serum IgE. Critically, they demonstrated that carrying risk alleles at all three loci — 5q31, 1q23 (FCER1A, the high-affinity IgE receptor), and 12q13 (STAT6) — elevates IgE risk fourfold, establishing that the 5q31 signal is most clinically meaningful when interpreted in the context of the broader atopic genetic landscape.

Cross-ethnic replication came from a Chinese Han study by Jiang et al. (2017)⁹⁹ Jiang et al. (2017)
Jiang XY et al. Asian Pac J Allergy Immunol 2017 of 3,013 atopic dermatitis cases and 5,483 controls, which confirmed a 5q31 RAD50/IL13 signal (rs2158177, a neighboring variant in strong LD, OR=1.15, P=1.08×10⁻³) for atopic dermatitis. The IL13 coding variant rs20541 — which produces the Gln144Arg amino acid change that reduces IL-13's affinity for its decoy receptor IL-13Rα2 and increases bioavailability — was independently confirmed as an atopic dermatitis risk variant by Lee et al. (2020)¹⁰¹⁰ Lee et al. (2020)
Lee E et al. Ann Allergy Asthma Immunol 2020 in 1,252 cases and 2,064 controls (P<0.001 in pilot, replicated). This distinct coding variant at the same locus converges on the same pathway: more effective IL-13 signaling.

The review by Potaczek & Kabesch (2012)¹¹¹¹ Potaczek & Kabesch (2012)
Potaczek DP, Kabesch M. Clin Exp Allergy 2012 contextualizes rs2040704's locus as one of six major genomic determinants of IgE regulation, alongside FCER1A, STAT6, IL4RA, TNFRSF13C, and PYCARD. Variants at 5q31 account for IgE variation driven primarily by Th2 cytokine production capacity — a distinct mechanism from FCER1A (receptor density) or IL4RA (receptor signaling efficiency).

Practical Implications

The G allele at rs2040704 does not diagnose allergy — it lowers the threshold at which allergen exposure tips into sensitization and sustained allergic inflammation. The most actionable implications concern early detection of atopic march progression and immune modulation strategies targeted at the IL-4/IL-13 axis.

Children with the GG genotype and early eczema have elevated biological risk for progression to food allergy and asthma — early allergen introduction protocols and barrier management become particularly relevant. Adults with the G allele who have never developed overt atopy may still carry subclinically elevated IgE that sensitizes them to new allergen exposures (occupational, pet, or seasonal) faster than non-carriers.

The therapeutic relevance is also increasing: biologics targeting this exact pathway — dupilumab (anti-IL-4Rα, blocks both IL-4 and IL-13 signaling), tralokinumab (anti-IL-13), and cendakimab — are now licensed for atopic dermatitis and/or asthma. G allele carriers who develop refractory atopic disease are biologically well-matched to this drug class, since the upstream genetic fault is in IL-13/IL-4 production rather than IgE receptor density or downstream signaling efficiency.

Interactions

rs2040704 at the 5q31 locus interacts multiplicatively with rs2228570/rs731236 (VDR) — vitamin D receptor variants that modulate Th2/Treg balance — and with rs20541 (IL13 R130Q), the coding variant ~23 kb downstream that determines IL-13 bioavailability independently of this regulatory variant. The combination of elevated IL-13 production (this locus) and reduced IL-13 clearance (rs20541 G allele, which reduces affinity for the decoy receptor) is a mechanistically coherent double hit for sustained Th2 inflammation.

Carriers who also have FCER1A rs2427827 or IL4RA rs1801275 risk alleles show the fourfold IgE elevation documented by Sharma et al. — a compound atopic signature where production, clearance, receptor density, and receptor signaling are all shifted toward the allergic pole.